Phase II Trial for Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) Treated With Gliadel Followed by Concurrent Radiation Therapy, Temodar and Avastin, Then Followed by Avastin and Temodar Post-Radiation.

Trial Profile

Phase II Trial for Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) Treated With Gliadel Followed by Concurrent Radiation Therapy, Temodar and Avastin, Then Followed by Avastin and Temodar Post-Radiation.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Carmustine polifeprosan 20 wafer (Primary) ; Bevacizumab; Temozolomide
  • Indications Glioblastoma; Gliosarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jan 2017 Planned End Date changed from 1 Jan 2017 to 1 Jun 2018.
    • 16 Jul 2016 Planned End Date changed from 1 Jun 2016 to 1 Jan 2017.
    • 20 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top